Tresiba Pre-Surgery Hold Window: Insulin Degludec Perioperative Dosing Guide

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin analog (U-100 and U-200 formulations) approved by the FDA for once-daily use in type 1 and type 2 diabetes. It is not the same molecule as insulin glargine (Lantus, Basaglar, Toujeo), insulin detemir (Levemir), or NPH insulin, and perioperative plans written for those products do not transfer directly to degludec.

Insulin degludec should not be stopped before surgery. The evidence-consistent approach, reflected in the American Diabetes Association's 2024 Standards of Care for hospital diabetes management, is to reduce the basal dose rather than omit it, and to continue a reduced dose through the period the patient is not eating.¹ Because degludec's terminal half-life is around 25 hours, roughly double that of glargine U-100, a dose reduction made the evening before surgery only partially offsets insulin already carried forward from the prior one to two days. This carry-forward property is the single fact that makes degludec's perioperative planning different from other basal insulins, and it is the reason a generic "reduce basal insulin by 20%" instruction, written for a shorter-acting product, can be misleading if applied unchanged to degludec.

This article is educational. It does not replace an individualized order from the prescribing clinician, endocrinologist, or anesthesia team, and none of the numbers below should be used to write an actual patient order without that confirmation.

What Is Established, What Is Plausible, and What Is Not Established

Established from the FDA label and pharmacology: Insulin degludec has a half-life of approximately 25 hours and a flat, prolonged action profile, reaching steady state after about 2 to 3 days of once-daily dosing, according to its prescribing information. It is approved for once-daily subcutaneous injection only; splitting or converting it to twice-daily dosing perioperatively is not an approved use and is not supported by the label.

Established from ADA guidance: Basal insulin, as a class, should generally be continued at a reduced dose during the perioperative period in hospitalized patients rather than withheld outright, with intraoperative and inpatient glucose targets typically in the 140 to 180 mg/dL range for most non-critically ill surgical patients.¹ The ADA guidance is written at the level of basal insulin as a class; it does not specify a degludec-specific percentage reduction.

Plausible but not degludec-specific: A 20 to 25% basal dose reduction the night before major surgery is a widely used convention in perioperative diabetes management. It is reasonable to apply to degludec, but no dedicated randomized trial has tested degludec-specific perioperative dosing protocols against an alternative reduction schedule. The exact percentage that best balances hyperglycemia and hypoglycemia risk for degludec specifically has not been established in a controlled trial.

Not established: Precise hypoglycemia or cardiovascular event rates attributable to degludec in the perioperative window specifically. Large outcome trials comparing degludec with glargine U-100 (commonly referenced by name as the DEVOTE and SWITCH trials) reported differences in nocturnal and overall hypoglycemia in general outpatient populations, not in surgical or NPO patients. Readers and clinicians who want the exact effect sizes, confidence intervals, or enrolled population details from those trials should verify them against the primary publications rather than relying on secondhand figures, since those specific numbers could not be confirmed against a verified source for this article.

Why the Half-Life Difference Matters More Than It Sounds

Glargine U-100 has an effective duration of roughly 20 to 24 hours, and detemir is similar. A dose reduction made the night before surgery for either of those products largely clears any residual activity by the following evening. Degludec's approximately 25-hour half-life means a dose given two evenings before surgery is still contributing meaningfully to circulating insulin activity on the day of the operation. A single-night dose adjustment addresses only part of the insulin actually on board. This is a boundary condition specific to degludec and to other very long half-life basal insulins; it does not apply the same way to glargine, detemir, or NPH.

A Practical Decision Framework

The framework below organizes the few facts that actually change perioperative management: procedure type, insulin-on-board carryover, and patient-specific risk. It is a structure for a conversation with the prescribing clinician and surgical team, not a standing order.

Step 1: Classify the procedure by fasting duration and anesthesia type.

• Minor outpatient procedure, local anesthesia, oral intake resumes within a few hours: a smaller reduction (commonly cited around 20%) for the prior evening's dose is a reasonable starting point for discussion, with no additional dose typically needed the morning of an early procedure.
• Major surgery, general or neuraxial anesthesia, NPO expected beyond 8 hours: a larger reduction (commonly cited around 20 to 25%) the evening before is the usual starting point, continued through the NPO period rather than stopped.
• Emergency surgery: assume a recent full dose may be on board. Point-of-care glucose should be checked immediately, and an intravenous insulin infusion protocol should be used if glucose is significantly elevated, per the treating institution's inpatient hyperglycemia protocol.

Step 2: Confirm the reduction is proportional, not an omission. A percentage reduction preserves basal coverage; skipping the dose entirely does not. This distinction matters most in type 1 diabetes, where even a short period without basal insulin can allow ketogenesis to begin, since there is no residual endogenous insulin secretion to fall back on. Complete omission of basal insulin in type 1 diabetes going into a fasting surgical period is not a supported strategy and should be treated as a red flag requiring immediate clinical correction, not a cost-saving or convenience option.

Step 3: Decide whether a morning-of dose is needed. For morning surgeries, the reduced prior-evening dose is generally expected to carry coverage through the early operative period given degludec's duration of action, so an additional morning dose is often unnecessary. For afternoon surgeries in type 1 diabetes with a rising glucose trend, a small supplemental dose may be considered, but this decision should be made jointly by the endocrinology and anesthesia teams on the day, based on real-time glucose readings, not decided in advance from a table.

Step 4: Set the monitoring interval to match risk. More frequent point-of-care glucose checks (commonly every 1 to 2 hours) are appropriate in type 1 diabetes, renal impairment, or when any dose adjustment is being tested for the first time. Less frequent checks (every 2 to 4 hours) may be reasonable in stable type 2 diabetes on lower-risk regimens. Continuous glucose monitors are not currently approved for making intraoperative dosing decisions; point-of-care glucometry remains the standard during the operative period itself, with CGM resuming as an adjunct afterward.

Step 5: Restart deliberately, not by doubling up. Once oral intake resumes, the usual pre-surgery dose is restarted at the next scheduled injection time. A missed or reduced dose during the NPO period is not "made up" with an extra dose; doing so raises hypoglycemia risk without a clear benefit.

Exceptions that should change the plan:

• Type 1 diabetes: never omit basal insulin, even for a short fast. A reduced dose is the floor, not an option to skip.
• Advanced kidney disease (eGFR below 30): insulin clearance is reduced, so a given dose lasts longer and hypoglycemia risk rises. Clinical convention favors a larger reduction and closer monitoring in this group, but the exact percentage is a matter of clinical judgment rather than a trial-derived figure, and should be individualized.
• Older adults: lower and less predictable carbohydrate intake and variable renal function argue for a more conservative (larger) reduction and a slightly higher glucose target floor to avoid unrecognized hypoglycemia, though this is a matter of clinical caution rather than a specific tested protocol.
• High total daily dose (obesity, insulin resistance): the same percentage reduction removes a larger absolute number of units, so the practical effect on glucose can be more noticeable; monitoring frequency, not the percentage itself, is usually the lever that changes.

When to treat this as urgent, not routine: glucose below 70 mg/dL at any point before or after the dose adjustment, symptoms of hypoglycemia, glucose persistently above 300 mg/dL, or any suspicion of diabetic ketoacidosis (nausea, vomiting, abdominal pain, rapid breathing) in a person with type 1 diabetes. These situations require contacting the care team or seeking urgent care rather than following a written schedule.

What ADA Guidance Actually Says About Targets

The ADA's 2024 Standards of Care for hospital diabetes management recommend glucose targets of roughly 140 to 180 mg/dL for most non-critically ill hospitalized and surgical patients, continuing basal insulin at a reduced rather than omitted dose during the perioperative period.¹ The American Association of Clinical Endocrinology has also published perioperative glucose management guidance; readers can consult AACE's site directly for current specifics, since the precise numeric targets in circulation vary by source and by patient population (for example, tighter targets are sometimes discussed for cardiac surgery), and should be confirmed against the current AACE document rather than assumed.⁴

Communicating the Plan to Patients

A useful patient instruction specifies three things: the exact dose to take the evening before the procedure, whether any dose is needed the morning of surgery, and a clear threshold and phone number for when to call before arriving at the hospital. For example, a patient taking degludec 28 units nightly might be told to take a reduced dose (for instance, 21 to 22 units, reflecting roughly a 20 to 25% reduction) the evening before, to skip the morning-of dose for an early procedure, and to call the office if glucose falls below 70 mg/dL or rises above 300 mg/dL. This is an illustrative example, not a specific order; the actual dose must come from the prescribing clinician.

Summary Table

Do not omit the basal dose entirely at any point on this table for a patient with type 1 diabetes.

References

1. American Diabetes Association. Diabetes Care in the Hospital: Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S295-S306. https://diabetesjournals.org/care/article/47/Supplement_1/S295/153970/16-Diabetes-Care-in-the-Hospital
2. American Association of Clinical Endocrinology. https://www.aace.com

Note for editorial and medical review: statistics attributed in earlier drafts to specific trials (DEVOTE, SWITCH 1/2, degludec-versus-glargine meta-analyses, renal pharmacokinetic studies, and a medication-instruction error-reduction trial) have been removed or generalized because the inherited citation identifiers could not be verified against the correct source paper and a targeted PubMed search did not return a confirming result. If a reviewer has access to the verified primary publications, the specific effect sizes and confidence intervals can be reinstated with correct, checked citations.